Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.

Vanachayangkul P, Lon C, Spring M, Sok S, Ta-Aksorn W, Kodchakorn C, Pann ST, Chann S, Ittiverakul M, Sriwichai S, Buathong N, Kuntawunginn W, So M, Youdaline T, Milner E, Wojnarski M, Lanteri C, Manning J, Prom S, Haigney M, Cantilena L, Saunders D.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02000-16. doi: 10.1128/AAC.02000-16. Print 2017 May.

2.

Safety and performance benefits of arginine supplements for military personnel: a systematic review.

Brooks JR, Oketch-Rabah H, Low Dog T, Gorecki DK, Barrett ML, Cantilena L, Chung M, Costello RB, Dwyer J, Hardy ML, Jordan SA, Maughan RJ, Marles RJ, Osterberg RE, Rodda BE, Wolfe RR, Zuniga JM, Valerio LG Jr, Jones D, Deuster P, Giancaspro GI, Sarma ND.

Nutr Rev. 2016 Nov;74(11):708-721. Review.

PMID:
27753625
3.

Prolonged Neuropsychiatric Symptoms in a Military Service Member Exposed to Mefloquine.

Livezey J, Oliver T, Cantilena L.

Drug Saf Case Rep. 2016 Dec;3(1):7.

4.

2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st Annual Report.

Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M.

Clin Toxicol (Phila). 2014 Dec;52(10):1032-283. doi: 10.3109/15563650.2014.987397.

5.

Poisoning in the United States: 2012 emergency medicine report of the National Poison Data System.

Dart RC, Bronstein AC, Spyker DA, Cantilena LR, Seifert SA, Heard SE, Krenzelok EP.

Ann Emerg Med. 2015 Apr;65(4):416-22. doi: 10.1016/j.annemergmed.2014.11.001. Epub 2014 Dec 15.

PMID:
25523411
6.

Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.

Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, Se Y, Somethy S, Phann ST, Chann S, Sriwichai S, Buathong N, Kuntawunginn W, Mitprasat M, Siripokasupkul R, Teja-Isavadharm P, Soh E, Timmermans A, Lanteri C, Kaewkungwal J, Auayporn M, Tang D, Chour CM, Prom S, Haigney M, Cantilena L, Saunders D.

Antimicrob Agents Chemother. 2014 Oct;58(10):6056-67. doi: 10.1128/AAC.02667-14. Epub 2014 Aug 4.

7.

Evidence-based evaluation of potential benefits and safety of beta-alanine supplementation for military personnel.

Ko R, Low Dog T, Gorecki DK, Cantilena LR, Costello RB, Evans WJ, Hardy ML, Jordan SA, Maughan RJ, Rankin JW, Smith-Ryan AE, Valerio LG Jr, Jones D, Deuster P, Giancaspro GI, Sarma ND.

Nutr Rev. 2014 Mar;72(3):217-25. Review.

PMID:
24697258
8.

2012 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th Annual Report.

Mowry JB, Spyker DA, Cantilena LR Jr, Bailey JE, Ford M.

Clin Toxicol (Phila). 2013 Dec;51(10):949-1229. doi: 10.3109/15563650.2013.863906.

PMID:
24359283
9.

A review of pharmaceutical labeling for overdose treatment and toxicity data.

Mazer-Amirshahi M, Sokol G, van den Anker J, Cantilena L.

Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):319-23. doi: 10.1002/pds.3398. Epub 2013 Jan 2.

PMID:
23283832
10.

2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report.

Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC.

Clin Toxicol (Phila). 2012 Dec;50(10):911-1164. doi: 10.3109/15563650.2012.746424. Erratum in: Clin Toxicol (Phila). 2014 Dec;52(10):1286-7.

PMID:
23272763
11.

Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants.

Cantilena L, Kahn R, Duncan CC, Li SH, Anderson A, Elkashef A.

J Addict Med. 2012 Dec;6(4):265-73. doi: 10.1097/ADM.0b013e31826b767f.

12.

Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study.

Miller RS, Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Melendez V, Smith B, Weina PJ.

Malar J. 2012 Aug 1;11:255. doi: 10.1186/1475-2875-11-255.

13.

2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report.

Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC.

Clin Toxicol (Phila). 2011 Dec;49(10):910-41. doi: 10.3109/15563650.2011.635149. Erratum in: Clin Toxicol (Phila). 2014 Dec;52(10):1285.

PMID:
22165864
14.

Assessment of the relative potency of fentanyl buccal tablet to intravenous morphine in healthy volunteers using a thermally induced hyperalgesia pain model.

Saunders DL, Messina J, Darwish M, Xie F, Leary KJ, Cantilena LR.

J Clin Pharmacol. 2012 Jun;52(6):870-9. doi: 10.1177/0091270011407496. Epub 2011 Jun 6.

PMID:
21646442
15.

2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report.

Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL.

Clin Toxicol (Phila). 2010 Dec;48(10):979-1178. doi: 10.3109/15563650.2010.543906. Erratum in: Clin Toxicol (Phila). 2014 Dec;52(10):1284.

PMID:
21192756
16.

2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report.

Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL.

Clin Toxicol (Phila). 2009 Dec;47(10):911-1084. doi: 10.3109/15563650903438566.

PMID:
20028214
17.

Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase I study.

Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Miller RS, Melendez V, Weina PJ.

Am J Trop Med Hyg. 2009 Oct;81(4):615-21. doi: 10.4269/ajtmh.2009.09-0150.

PMID:
19815876
18.

A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers.

Leary KJ, Riel MA, Roy MJ, Cantilena LR, Bi D, Brater DC, van de Pol C, Pruett K, Kerr C, Veazey JM Jr, Beboso R, Ohrt C.

Am J Trop Med Hyg. 2009 Aug;81(2):356-62.

PMID:
19635898
19.

2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report.

Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE; American Association of Poison Control Centers.

Clin Toxicol (Phila). 2008 Dec;46(10):927-1057. doi: 10.1080/15563650802559632.

PMID:
19065310
20.

2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS).

Bronstein AC, Spyker DA, Cantilena LR Jr, Green J, Rumack BH, Heard SE.

Clin Toxicol (Phila). 2007 Dec;45(8):815-917.

PMID:
18163234
21.

High performance liquid chromatographic measurement of iothalamate in human serum and urine for evaluation of glomerular filtration rate.

Bi D, Leary KJ, Weitz JA, Cherstniakova SA, Reil MA, Roy MJ, Cantilena LR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):95-9. Epub 2007 Jun 6.

PMID:
17599846
22.

Prevalence of abnormal liver-associated enzymes in cocaine experienced adults versus healthy volunteers during phase 1 clinical trials.

Cantilena LR, Cherstniakova SA, Saviolakis G, Kahn R, Elkashef A, Rose L, Vocci F.

Contemp Clin Trials. 2007 Nov;28(6):695-704. Epub 2007 Mar 19.

PMID:
17544338
23.

Pyridostigmine, diethyltoluamide, permethrin, and stress: a double-blind, randomized, placebo-controlled trial to assess safety.

Roy MJ, Kraus PL, Seegers CA, Young SY, Kamens DR, Law WA, Cherstniakova SA, Chang DN, Cooper JA, Sato PA, Matulich W, Krantz DS, Cantilena LR, Deuster PA.

Mayo Clin Proc. 2006 Oct;81(10):1303-10.

PMID:
17036555
24.

Intravenous cocaine and QT variability.

Haigney MC, Alam S, Tebo S, Marhefka G, Elkashef A, Kahn R, Chiang CN, Vocci F, Cantilena L.

J Cardiovasc Electrophysiol. 2006 Jun;17(6):610-6.

PMID:
16836708
25.
26.

Initial evaluation of N,N-diethyl-m-toluamide and permethrin absorption in human volunteers under stress conditions.

Roy MJ, Kraus PL, Cooper JA, Cherstniakova S, Coll R, Seegers CA, Deuster PA, Koslowe P, Law WA, Krantz DS, Cantilena L.

Mil Med. 2006 Feb;171(2):122-7.

PMID:
16578980
27.

The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.

Knudsen JF, Carlsson U, Hammarström P, Sokol GH, Cantilena LR.

Inflammation. 2004 Oct;28(5):285-90.

PMID:
16134002
28.

The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval.

Beasley CM Jr, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turik MA, Bakhtyari A, Warner MR, Ruskin JN, Cantilena LR Jr, Kloner RA.

J Am Coll Cardiol. 2005 Aug 16;46(4):678-87.

29.

Metabolism by N-acetyltransferase 1 in vitro and in healthy volunteers: a prototype for targeted inhibition.

Cantilena LR, Katki AG, Klecker RW, Collins JM.

J Clin Pharmacol. 2004 Dec;44(12):1405-11.

PMID:
15545312
30.

Drug-induced torsades de pointes and implications for drug development.

Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR; Independent Academic Task Force.

J Cardiovasc Electrophysiol. 2004 Apr;15(4):475-95. Review.

31.

Adverse events following discharge from the hospital.

Medlock MM, Cantilena LR Jr, Riel MA.

Ann Intern Med. 2004 Feb 3;140(3):231-2; author reply 232-3. No abstract available.

PMID:
14757626
32.

Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes.

Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR.

Drug Metab Dispos. 2001 Sep;29(9):1216-20.

PMID:
11502731
33.

Assessment and reporting of clinical pharmacology information in drug labeling.

Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, Atkinson AJ Jr, Woosley RL, Abernethy DR, Cantilena LR.

Clin Pharmacol Ther. 2000 Mar;67(3):196-200. No abstract available.

PMID:
10741621
34.

The effectiveness of antihistamines in reducing the severity of runny nose and sneezing: a meta-analysis.

D'Agostino RB Sr, Weintraub M, Russell HK, Stepanians M, D'Agostino RB Jr, Cantilena LR Jr, Graumlich JF, Maldonado S, Honig P, Anello C.

Clin Pharmacol Ther. 1998 Dec;64(6):579-96. No abstract available.

PMID:
9871423
35.

A drug interaction between zafirlukast and theophylline.

Katial RK, Stelzle RC, Bonner MW, Marino M, Cantilena LR, Smith LJ.

Arch Intern Med. 1998 Aug 10-24;158(15):1713-5.

PMID:
9701106
36.

Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion.

Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR Jr, Wang Y, Levine M.

Pharm Res. 1997 Sep;14(9):1133-9.

PMID:
9327438
37.

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.

Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL.

J Clin Oncol. 1997 Apr;15(4):1492-501.

PMID:
9193345
38.

Clinical pharmacology of 9-aminocamptothecin.

Takimoto CH, Dahut W, Harold N, Nakashima H, Lieberman R, Liang MD, Arbuck SG, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL.

Ann N Y Acad Sci. 1996 Dec 13;803:324-6. No abstract available.

PMID:
8993530
39.

Survey of clinical pharmacology training in the United States and Canada.

Cantilena LR Jr, Woosley RL.

Clin Pharmacol Ther. 1996 Jul;60(1):1-7.

PMID:
8689805
40.

Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance.

Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR.

Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3704-9.

41.

Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.

Honig PK, Wortham DC, Lazarev A, Cantilena LR.

J Clin Pharmacol. 1996 Apr;36(4):345-51.

PMID:
8728348
42.

Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram.

Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL.

Clin Pharmacol Ther. 1996 Apr;59(4):383-8.

PMID:
8612381
43.

Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.

Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR Jr, Grem JL, Allegra CJ, Diasio RB, Chu E.

Clin Cancer Res. 1996 Mar;2(3):477-81.

44.

Panic disorder in a patient taking oxaprozin.

Hough DW, Sellers R, Cantilena LR.

Am J Psychiatry. 1995 Jan;152(1):149. No abstract available.

PMID:
7802107
45.

Ketoconazole and fluconazole drug interactions.

Honig PK, Cantilena LR.

Arch Intern Med. 1994 May 9;154(9):1038, 1041. No abstract available.

PMID:
8179450
46.

Antipyrine as a model drug substance to assess oxidative metabolism.

Konig PK, Cantilena L.

Arch Intern Med. 1994 Mar 14;154(5):590. No abstract available.

PMID:
8122953
47.

Polypharmacy. Pharmacokinetic perspectives.

Honig PK, Cantilena LR.

Clin Pharmacokinet. 1994 Feb;26(2):85-90. Review. No abstract available.

PMID:
8162659
48.

Population variability in the pharmacokinetics of terfenadine: the case for a pseudo-polymorphism with clinical implications.

Honig PK, Smith JE, Wortham DC, Zamani K, Cantilena LR.

Drug Metabol Drug Interact. 1994;11(2):161-8.

PMID:
12369599
49.

Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics.

Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR.

J Clin Pharmacol. 1993 Dec;33(12):1201-6.

PMID:
8126255
50.

The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans.

Honig PK, Worham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR.

Clin Pharmacol Ther. 1993 Jun;53(6):630-6.

PMID:
8513654

Supplemental Content

Loading ...
Support Center